AFECTAREA CARDIOVASCULARĂ LA PACIENȚII CU SCLERODERMIE SISTEMICĂ
DOI:
https://doi.org/10.52692/1857-0011.2022.1-72.26Cuvinte cheie:
sclerodermie sistemică, tulburări vasospastice, afectarea cardiovascularăRezumat
Sclerodermia sistemică este o boală generalizată a țesutului conjunctiv caracterizată prin exprimarea manifestărilor patologice ale pielii, sistemului musculo-scheletic cu afectarea cordului, plămânilor, rinichilor, tractului gastrointestinal și tulburări vasospastice difuze cauzate de afectarea țesutului conjunctiv, predominând fibroza de tip microangiopatie obliterantă. Manifestările cardiovasculare au fost remarcate la aproximativ 10% dintre pacienții cu sclerodermie sistemică, fiind un predictor important al mortalității pacientului și adesea asociat cu un prognostic nefavorabil.
Referințe
Groppa L. et al. Protocol clinic național: Sclerodermia sistemică la adult., 2018; PCN-90: 6.
Careta M., Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol., 2015; 90(1):62-73.
Rongioletti F., Ferreli C., Atzori L., et. al. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol., 2018; 153:208
Bergamasco A., Hartmann N., Wallace L., et al. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol., 2019; 11:257-273.
Medsger T., Masi A. The epidemiology of systemic sclerosis (scleroderma). Ann Intern Med., 1971; 74:714-21.
Heine J. Uber ein eigenartiges Krankheitsbild von deiffuser Sklerosis der haut and innerer organe. Virchows Arch., 1926; 262:1.
Čolić J., Matucci C. et al. Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question! J Scleroderma Relat Disord., 2020; 5: 6-20.
Sgonc R., Gruschwitz M.S., Boeck G. et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody‐dependent cell‐mediated cytotoxicity via CD95. Arthritis Rheum., 2000; 43: 2550–62.
Katsumoto T., Whitfield M. and Connolly M. The pathogenesis of systemic sclerosis. Annual Review of Pathology: Mechanisms of Disease., 2011; 6: 509–537.
Desai C., Lee D., Shah S. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol., 2011; 23(6):545.
Tyndall A., Bannert B., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis., 2010; 69:1809–1815.
Roberts N., Cabeen W. Jr, Moss J. et al. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med., 1981; 94:38–40.
Gowda R., Khan I. et al. Scleroderma pericardial disease presented with a large pericardial effusion—a case report. Angiology., 2001; 52:59-62.
Morrisroe K., Stevens W. et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening program. Arthritis Res Ther., 2017; 19(1):42.
Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest, 2013;144(4):1346-1356.
De Groote P., Gressin V., Hachulla E., et al; ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis., 2008; 67(1):31-36.
Cannarile F., Valentini V., Mirabelli G., et al. Cardiovascular disease in systemic sclerosis. Ann Transl Med. 2015;3(1):8. doi:10.3978/j.issn.2305-5839.2014.12.12).
Ngian G., Sahhar J. et al. Cardiovascular disease in systemic sclerosis. Ann Rheum Dis., 2015 Dec; 71(12):1980-3.
Sponga S., Basso C., Ruffatti A., Gerosa G. Systemic sclerosis and aortic valve stenosis: therapeutic implications in two cases of aortic valve replacement. J Cardiovasc Med (Hagerstown)., 2009; 10:560–562.
Descărcări
Publicat
Număr
Secțiune
Licență
Copyright (c) 2022 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
